NCT00715078 - To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

May 31, 2015

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

sipuleucel-T

Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)

Trial Locations (12)

10029

Mount Sinai School of Medicine, New York

10032

Columbia University Medical Center, New York

20007

Georgetown University Medical Center, Washington D.C.

23503

Urology of Virginia, Sentara Medical Group, Norfolk

46202

Indiana University, Indianapolis

92123

Sharp Clinical Oncology Research, San Diego

97213

Providence Medical Center, Portland

97227

Kaiser Permanente, Portland

Northwest Cancer Specialists, Portland

98101

Virginia Mason Medical Center Urology and Renal Transplantation, Seattle

98102

Seattle Cancer Care Alliance, Seattle

92093-0820

UCSD Moores Cancer Center, La Jolla